Skip to contentScholarGate
LibraryBookshelfDeskReview StudioAssistant
Sign in
On this page
IntuitionHow it worksWhen to use itStrengths & limitationsCommon pitfallsApplicationsFrequently asked🔒 Read the full methodSourcesRelated methods
Cite this pageSpotted an issue on this page? Report or suggest a fix →
Home›Bioinformatics›Differential Proteomics Analysis — Comparing Protein Abundance Across Conditions
Process / pipelineBioinformatics / omics

Differential Proteomics Analysis — Comparing Protein Abundance Across Conditions

Differential Proteomics Analysis · Also known as: comparative proteomics, quantitative differential proteomics, differential protein expression analysis, DPA

Differential proteomics analysis is a quantitative pipeline that identifies proteins whose abundance levels change significantly between two or more biological conditions — such as healthy versus diseased tissue, treated versus untreated cells, or different developmental stages. By combining mass spectrometry-based detection with statistical testing, the method generates ranked lists of differentially expressed proteins that can be linked to biological pathways, disease mechanisms, or drug targets.

ScholarGate
  1. Process / pipeline
  2. v1
  3. 2 Sources
  4. PUBLISHED
Cite this page →
Tools & resources
Download slides
Learn & explore

Read the full method

Members only

Sign in with a free account to read this section.

Sign in

Method map

The neighbourhood of related methods — select a node to explore.

Differential proteomics analysis
Pathway Enrichment Analy…Differential Metabolomic…

When to use it

Differential proteomics is appropriate when the research goal is to identify which proteins change in abundance between defined biological states — disease onset, drug treatment, genetic perturbation, or developmental transition — and to link those changes to functional pathways. It requires biological replicates (minimum 3 per group; 4–6 preferred) and access to LC-MS/MS infrastructure or publicly deposited datasets. Use it when transcriptomic data alone is insufficient because post-transcriptional regulation is suspected, or when protein-level evidence is required for biomarker validation. Do not use it as a primary discovery tool when sample numbers are very small (n < 3 per group) without acknowledging severely limited statistical power; for targeted quantification of a small known protein panel, targeted proteomics (PRM/SRM) is more appropriate.

Strengths & limitations

Strengths
  • Directly measures protein abundance rather than inferring it from mRNA, capturing post-transcriptional and post-translational regulation.
  • Modern LC-MS/MS workflows can identify and quantify thousands of proteins simultaneously in a single experiment.
  • Label-based multiplexing (TMT, iTRAQ) reduces technical variation by running multiple samples in one MS injection.
  • Statistical frameworks adapted from transcriptomics (e.g., limma) are well-validated and handle small biological replicates better than naive t-tests.
  • Integrates naturally with pathway, network, and GO enrichment tools for rapid biological interpretation.
Limitations
  • MS-based proteomics has a dynamic range limitation: very low-abundance proteins (e.g., transcription factors, signalling intermediates) are frequently missed unless enrichment steps are added.
  • Quantification accuracy depends heavily on sample preparation consistency; variability in digestion or labelling efficiency introduces systematic bias.
  • Label-free approaches require careful chromatographic reproducibility; batch effects across runs can confound comparisons if not normalised.
  • Protein inference from shared peptides (the protein grouping problem) can complicate quantification for protein families with high sequence similarity.

Frequently asked

What is the difference between label-based and label-free differential proteomics?

Label-based methods (SILAC, TMT, iTRAQ) introduce stable isotope tags that allow multiple samples to be mixed and measured in the same MS run, reducing run-to-run technical variation and enabling direct intensity ratios. Label-free approaches quantify each sample in a separate run and compare intensities computationally; they require no specialised reagents and scale easily to large cohorts but demand strict chromatographic reproducibility and robust normalisation to control batch effects.

How many biological replicates do I need?

A minimum of three biological replicates per condition is required for any statistical inference; four to six replicates are strongly recommended for discovery experiments with moderate expected effect sizes. With only two replicates per group, variance cannot be reliably estimated and moderated tests offer little advantage. Power calculation tools such as PANDA or ProPower can help determine the sample size needed to detect a target fold change at a given FDR.

How should I handle proteins that are detected in one condition but completely absent in another?

Proteins present in all replicates of one condition but absent from all replicates of the other ('all-or-nothing' proteins) represent a biologically important class. They should not be discarded. A common approach is to impute missing values from a low-intensity distribution (e.g., random draws from the 5th percentile of detected intensities) before statistical testing, and to report these proteins separately with clear annotation that they were subject to imputation.

What statistical test should I use for differential proteomics?

The limma moderated t-test (originally developed for microarray data) is the most widely recommended approach for small-to-moderate sample sizes because it borrows variance information across all proteins to stabilise per-protein estimates. For larger datasets (n > 10 per group) ordinary t-tests or Wilcoxon tests perform comparably. DEqMS extends limma by weighting variance estimates by the number of peptides used for quantification, which can improve accuracy. Always apply Benjamini-Hochberg FDR correction for multiple comparisons.

Can I integrate differential proteomics results with RNA-seq data?

Yes — multi-omics integration is a major application. After identifying differentially expressed proteins and differentially expressed genes separately, overlap and correlation analyses reveal whether changes are driven at the transcriptional or post-transcriptional level. Tools such as OmicsIntegrator, MOFA, or simple Pearson correlation between matched mRNA and protein fold changes are commonly used. Proteins that change without corresponding mRNA changes are candidates for regulation by translation efficiency, protein stability, or post-translational modifications.

Sources

  1. Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., & Mann, M. (2002). Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Molecular & Cellular Proteomics, 1(5), 376–386. DOI: 10.1074/mcp.M200025-MCP200 ↗
  2. Bantscheff, M., Lemeer, S., Savitski, M. M., & Kuster, B. (2012). Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Analytical and Bioanalytical Chemistry, 404(4), 939–965. DOI: 10.1007/s00216-012-6203-4 ↗

How to cite this page

ScholarGate. (2026, June 3). Differential Proteomics Analysis. ScholarGate. https://scholargate.app/en/bioinformatics/differential-proteomics-analysis

Related methods

Pathway Enrichment Analysis

Which method?

Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.

  • Pathway Enrichment AnalysisBioinformatics↔ compare
Compare side by side →

Referenced by

Differential Metabolomics Analysis

Similar methods

Proteomics AnalysisTime-series proteomics analysisMulti-omics proteomics analysisDifferential Metabolomics AnalysisBayesian Proteomics AnalysisMulti-omics RNA-seq differential expressionMulti-omics Pathway Enrichment AnalysisDifferential pathway enrichment analysis

Related reference concepts

Quantitative Gene Expression AnalysisImmunohistochemistry and Protein Detection MethodsPathway Enrichment and Network AnalysisDrug Target IdentificationPost-Translational ModificationsFunctional Genomics and Pathway Analysis

Spotted an issue on this page? Report or suggest a fix →

ScholarGate — Differential proteomics analysis (Differential Proteomics Analysis). Retrieved 2026-07-21 from https://scholargate.app/en/bioinformatics/differential-proteomics-analysis · Dataset: https://doi.org/10.5281/zenodo.20539026
Quick facts
Originator
Pioneered broadly by Matthias Mann and colleagues; SILAC introduced by Ong et al. (2002)
Year
Late 1990s–2000s (mass spectrometry-based approaches matured ~1999–2004)
Type
Quantitative omics pipeline
DataType
Mass spectrometry intensity data (label-based or label-free); protein abundance tables
Subfamily
Bioinformatics / omics
Related methods
Pathway Enrichment Analysis
ScholarGate

A content-first reference library for research methods — what each one is, how it works, and where it comes from.

Open data (CC-BY)

Explore

  • Library
  • Search the library…
  • Browse by field
  • Fields
  • Journey
  • Compare
  • Which method?

Reference

  • Subjects
  • Atlas
  • Glossary
  • Methodology
  • Philosophy

Your tools

  • Bookshelf
  • Desk
  • Chat

Company

  • About
  • Pricing
  • Contact
  • Suggest a method

Entries are compiled from published sources for reference. Verifying the accuracy and suitability of any information for your own use remains your responsibility.

© 2026 ScholarGate · A research-method reference library
  • Privacy
  • Cookies
  • Terms
  • Delete account